Plain-English translation of NCT06979271 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether telitacicept combined with tofacitinib can help people whose rheumatoid arthritis hasn't improved with other treatments. Rheumatoid arthritis is a serious condition where the immune system attacks joints, causing pain, swelling, and damage. This study wants to see if using these two medications together works better and is safe for patients who haven't had success with other options.
Some people with rheumatoid arthritis don't get better even after trying multiple medications. This trial is looking for a new combination approach to help patients whose disease is hard to control and who need additional options.
You likely qualify if…
You likely don't qualify if…
You would take telitacicept combined with tofacitinib as prescribed by the study team. The trial will monitor how well the medication works for your arthritis and watch for any side effects. You'll likely have visits to the hospital or clinic for check-ins, blood tests, and assessments of how you're feeling and how your joints are doing.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China
Sponsor
Zhejiang Provincial People's Hospital
Enrollment target
~20 participants
Started
June 2025
Primary completion
April 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 85 Years
Last updated on clinicaltrials.gov in May 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.